AU2002320198B2 - New assays for preimplantation factor and preimplantation factor peptides - Google Patents
New assays for preimplantation factor and preimplantation factor peptides Download PDFInfo
- Publication number
- AU2002320198B2 AU2002320198B2 AU2002320198A AU2002320198A AU2002320198B2 AU 2002320198 B2 AU2002320198 B2 AU 2002320198B2 AU 2002320198 A AU2002320198 A AU 2002320198A AU 2002320198 A AU2002320198 A AU 2002320198A AU 2002320198 B2 AU2002320198 B2 AU 2002320198B2
- Authority
- AU
- Australia
- Prior art keywords
- antibody
- ser
- pif
- ile
- ala
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 238000003556 assay Methods 0.000 title claims abstract description 14
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 42
- GLXYOFXNKBTMQL-YKCHQESGSA-N (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-1-[(2S)-6-amino-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-methylbutanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-methylpentanoyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-4-oxobutanoyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]butanedioic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N1[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O)CCC1 GLXYOFXNKBTMQL-YKCHQESGSA-N 0.000 title claims description 20
- 102000004196 processed proteins & peptides Human genes 0.000 title description 13
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 claims abstract description 58
- 238000000684 flow cytometry Methods 0.000 claims abstract description 11
- 239000000427 antigen Substances 0.000 claims description 22
- 102000036639 antigens Human genes 0.000 claims description 22
- 108091007433 antigens Proteins 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 21
- 150000001413 amino acids Chemical class 0.000 claims description 16
- 241000124008 Mammalia Species 0.000 claims description 8
- 230000030279 gene silencing Effects 0.000 claims description 6
- 150000004492 retinoid derivatives Chemical class 0.000 claims description 5
- 101710117490 Circumsporozoite protein Proteins 0.000 claims description 3
- 238000002965 ELISA Methods 0.000 claims description 3
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 230000002829 reductive effect Effects 0.000 claims description 2
- 239000005495 thyroid hormone Substances 0.000 claims description 2
- 229940036555 thyroid hormone Drugs 0.000 claims description 2
- 102100026992 Dermcidin Human genes 0.000 abstract description 48
- 230000000694 effects Effects 0.000 abstract description 23
- 108010022347 proteolysis-inducing peptide Proteins 0.000 abstract description 23
- 230000015572 biosynthetic process Effects 0.000 abstract description 11
- 230000007423 decrease Effects 0.000 abstract description 6
- 230000003833 cell viability Effects 0.000 abstract description 4
- 230000003247 decreasing effect Effects 0.000 abstract description 4
- 230000000781 anti-lymphocytic effect Effects 0.000 abstract description 2
- 230000000702 anti-platelet effect Effects 0.000 abstract description 2
- 239000003146 anticoagulant agent Substances 0.000 abstract description 2
- 238000004113 cell culture Methods 0.000 abstract description 2
- 238000012360 testing method Methods 0.000 abstract description 2
- 238000012286 ELISA Assay Methods 0.000 abstract 1
- 239000000758 substrate Substances 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 22
- 239000000523 sample Substances 0.000 description 19
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 18
- 210000002257 embryonic structure Anatomy 0.000 description 16
- 210000001161 mammalian embryo Anatomy 0.000 description 16
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 14
- 238000004128 high performance liquid chromatography Methods 0.000 description 12
- 239000000499 gel Substances 0.000 description 11
- 230000035935 pregnancy Effects 0.000 description 11
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 10
- 230000035899 viability Effects 0.000 description 10
- 239000001963 growth medium Substances 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 239000000872 buffer Substances 0.000 description 7
- 230000004720 fertilization Effects 0.000 description 7
- 238000002513 implantation Methods 0.000 description 7
- 238000001042 affinity chromatography Methods 0.000 description 6
- 210000004698 lymphocyte Anatomy 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 201000004792 malaria Diseases 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 210000000287 oocyte Anatomy 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101001063392 Homo sapiens Lymphocyte function-associated antigen 3 Proteins 0.000 description 3
- 102100030984 Lymphocyte function-associated antigen 3 Human genes 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000006044 T cell activation Effects 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 210000002459 blastocyst Anatomy 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 102000004217 thyroid hormone receptors Human genes 0.000 description 3
- 108090000721 thyroid hormone receptors Proteins 0.000 description 3
- 238000000108 ultra-filtration Methods 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 241000223960 Plasmodium falciparum Species 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- UZMAPBJVXOGOFT-UHFFFAOYSA-N Syringetin Natural products COC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UZMAPBJVXOGOFT-UHFFFAOYSA-N 0.000 description 2
- 239000007997 Tricine buffer Substances 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 239000003636 conditioned culture medium Substances 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 description 2
- 230000013020 embryo development Effects 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 230000035558 fertility Effects 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 208000000509 infertility Diseases 0.000 description 2
- 231100000535 infertility Toxicity 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- QKFJKGMPGYROCL-UHFFFAOYSA-N phenyl isothiocyanate Chemical compound S=C=NC1=CC=CC=C1 QKFJKGMPGYROCL-UHFFFAOYSA-N 0.000 description 2
- 238000011533 pre-incubation Methods 0.000 description 2
- 230000004043 responsiveness Effects 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- CFBILACNYSPRPM-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[[1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl]amino]acetic acid Chemical compound OCC(N)(CO)CO.OCC(CO)(CO)NCC(O)=O CFBILACNYSPRPM-UHFFFAOYSA-N 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- NCQMBSJGJMYKCK-ZLUOBGJFSA-N Ala-Ser-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O NCQMBSJGJMYKCK-ZLUOBGJFSA-N 0.000 description 1
- 102100035248 Alpha-(1,3)-fucosyltransferase 4 Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102100036008 CD48 antigen Human genes 0.000 description 1
- 108010084313 CD58 Antigens Proteins 0.000 description 1
- 102100022002 CD59 glycoprotein Human genes 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241001622557 Hesperia Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001022185 Homo sapiens Alpha-(1,3)-fucosyltransferase 4 Proteins 0.000 description 1
- 101000716130 Homo sapiens CD48 antigen Proteins 0.000 description 1
- 101000897400 Homo sapiens CD59 glycoprotein Proteins 0.000 description 1
- 101100309604 Homo sapiens SCD5 gene Proteins 0.000 description 1
- 101000653542 Homo sapiens Transcription factor-like 5 protein Proteins 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
- 102100034104 Maestro heat-like repeat-containing protein family member 2B Human genes 0.000 description 1
- 101710091075 Maestro heat-like repeat-containing protein family member 2B Proteins 0.000 description 1
- 208000034702 Multiple pregnancies Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- -1 N-protected amino Chemical class 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 244000088415 Raphanus sativus Species 0.000 description 1
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 1
- 108091006629 SLC13A2 Proteins 0.000 description 1
- 101100101423 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) UBI4 gene Proteins 0.000 description 1
- 101150042597 Scd2 gene Proteins 0.000 description 1
- 102100033930 Stearoyl-CoA desaturase 5 Human genes 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 102100030647 Transcription factor-like 5 protein Human genes 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- CMQZRJBJDCVIEY-JEOLMMCMSA-N alpha-L-Fucp-(1->3)-[beta-D-Galp-(1->4)]-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-D-Glcp Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](CO)O[C@@H](O[C@@H]2[C@H]([C@H](O[C@@H]3[C@H](OC(O)[C@H](O)[C@H]3O)CO)O[C@H](CO)[C@@H]2O)O)[C@@H]1NC(C)=O CMQZRJBJDCVIEY-JEOLMMCMSA-N 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000001045 blue dye Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 125000000837 carbohydrate group Chemical group 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 101150117572 ced-2 gene Proteins 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000011026 diafiltration Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000032692 embryo implantation Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000005104 human peripheral blood lymphocyte Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000009027 insemination Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 102000006255 nuclear receptors Human genes 0.000 description 1
- 108020004017 nuclear receptors Proteins 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 230000003836 peripheral circulation Effects 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 229940117953 phenylisothiocyanate Drugs 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000012207 quantitative assay Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 102000027483 retinoid hormone receptors Human genes 0.000 description 1
- 239000012146 running buffer Substances 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 229960001814 trypan blue Drugs 0.000 description 1
- 238000003211 trypan blue cell staining Methods 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 210000004340 zona pellucida Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4715—Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70507—C2D
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Pregnancy & Childbirth (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Reproductive Health (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30260701P | 2001-07-02 | 2001-07-02 | |
| US60/302,607 | 2001-07-02 | ||
| PCT/US2002/020599 WO2003004601A2 (en) | 2001-07-02 | 2002-06-28 | New assays for preimplantation factor and preimplantation factor peptides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2002320198A1 AU2002320198A1 (en) | 2003-05-22 |
| AU2002320198B2 true AU2002320198B2 (en) | 2007-10-04 |
Family
ID=23168483
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2002320198A Expired AU2002320198B2 (en) | 2001-07-02 | 2002-06-28 | New assays for preimplantation factor and preimplantation factor peptides |
Country Status (12)
| Country | Link |
|---|---|
| US (8) | US7273708B2 (https=) |
| EP (1) | EP1404877B1 (https=) |
| JP (1) | JP4593106B2 (https=) |
| CN (5) | CN101059510A (https=) |
| AT (1) | ATE454399T1 (https=) |
| AU (1) | AU2002320198B2 (https=) |
| CA (1) | CA2490538C (https=) |
| DE (1) | DE60235011D1 (https=) |
| IL (6) | IL159671A0 (https=) |
| MX (1) | MXPA04000151A (https=) |
| NZ (1) | NZ530723A (https=) |
| WO (1) | WO2003004601A2 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8222211B2 (en) * | 2001-07-02 | 2012-07-17 | Bioincept, Llc | Methods of administering PIF agonist peptides and uses thereof |
| US7273708B2 (en) * | 2001-07-02 | 2007-09-25 | Bioincept, Llc | Assays for preimplantation factor and preimplantation factor peptides |
| US7723290B2 (en) * | 2004-10-22 | 2010-05-25 | Bioincept, Llc | Compositions and methods for modulating the immune system |
| EP1680442B1 (en) * | 2003-10-22 | 2011-07-13 | Bioincept, LLC. | Pif peptides biologic activities |
| WO2005040196A2 (en) | 2003-10-22 | 2005-05-06 | Bioincept, Llc | Pif peptides biologic activities, site of action, and the antibody to detect pif |
| US7723289B2 (en) * | 2003-10-22 | 2010-05-25 | Bioincept, Llc | PIF tetrapeptides |
| US9737585B2 (en) | 2011-03-02 | 2017-08-22 | Bioincept, Llc | Compositions and methods for treatment of intracellular damage and bacterial infection |
| WO2017039751A1 (en) | 2015-08-28 | 2017-03-09 | Bioincept, Llc | Mutant peptides and methods of treating subjects using the same |
| EP2970496B1 (en) | 2013-03-12 | 2018-07-18 | Institute of Arthritis Research LLC | Immunologically active polypeptide |
| AU2015343202A1 (en) * | 2014-11-03 | 2017-05-25 | Bioincept, Llc | PIF binding as a marker for immune dysregulation |
| EP3341006A4 (en) | 2015-08-28 | 2019-03-13 | BioIncept LLC | COMPOSITIONS AND METHODS FOR TREATING NERVE DAMAGE |
| CA3054366A1 (en) * | 2017-02-22 | 2018-08-30 | Bioincept, Llc | Peptides and methods of treating dystrophy-related disorders using the same |
| US20240228620A1 (en) | 2022-10-06 | 2024-07-11 | Bicara Therapeutics Inc. | Multispecific proteins and related methods |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US564003A (en) * | 1896-07-14 | chase | ||
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US5279941A (en) | 1992-06-12 | 1994-01-18 | Trustees Of The University Of Pennsylvania | Determination of endometrial receptivity toward embryo implantation |
| AU5130793A (en) * | 1992-09-17 | 1994-04-12 | New York University | Compositions and methods for inhibiting hepatocyte invasion by malarial sporozoites |
| US5646003A (en) | 1994-03-23 | 1997-07-08 | Barnea; Eytan R. | Preimplantation factor |
| GB9406492D0 (en) | 1994-03-31 | 1994-05-25 | Isis Innovation | Malaria peptides |
| US6489441B1 (en) * | 1995-09-01 | 2002-12-03 | The Salk Institute For Biological Studies | Transcriptional co-repressor that interacts with nuclear hormone receptors |
| US6585979B1 (en) | 1996-07-08 | 2003-07-01 | Genentech, Inc. | HIV envelope polypeptides and immunogenic composition |
| US6171591B1 (en) * | 1997-12-08 | 2001-01-09 | Pentamer Pharmaceuticals, Inc. | Recombinant nodavirus compositions and methods |
| US20020004205A1 (en) | 2000-03-30 | 2002-01-10 | Consler Thomas G. | Method of investigating functional molecular interactions and reagents for use therein |
| EP1355664A4 (en) | 2001-01-04 | 2005-10-26 | Vascular Biogenics Ltd | METHODS INVOLVING MOLECULES ASSOCIATED WITH ATHEROSCLEROSIS PLATES AND COMPOSITIONS CONTAINING THESE MOLECULES FOR THE PREVENTION AND TREATMENT OF ATHEROSCLEROSIS |
| US8222211B2 (en) | 2001-07-02 | 2012-07-17 | Bioincept, Llc | Methods of administering PIF agonist peptides and uses thereof |
| US7273708B2 (en) | 2001-07-02 | 2007-09-25 | Bioincept, Llc | Assays for preimplantation factor and preimplantation factor peptides |
| WO2004053086A2 (en) | 2002-12-06 | 2004-06-24 | Epimmune, Inc. | Plasmodium falciparum antigens and methods of use |
| US7156272B2 (en) * | 2003-08-22 | 2007-01-02 | Frank Dean | Golf bag carrier for a motorcycle |
| US7723289B2 (en) | 2003-10-22 | 2010-05-25 | Bioincept, Llc | PIF tetrapeptides |
| US7723290B2 (en) | 2004-10-22 | 2010-05-25 | Bioincept, Llc | Compositions and methods for modulating the immune system |
| WO2005040196A2 (en) | 2003-10-22 | 2005-05-06 | Bioincept, Llc | Pif peptides biologic activities, site of action, and the antibody to detect pif |
-
2002
- 2002-06-28 US US10/482,244 patent/US7273708B2/en not_active Expired - Lifetime
- 2002-06-28 DE DE60235011T patent/DE60235011D1/de not_active Expired - Lifetime
- 2002-06-28 CN CNA2007100864051A patent/CN101059510A/zh active Pending
- 2002-06-28 CN CNB028133196A patent/CN100339388C/zh not_active Expired - Lifetime
- 2002-06-28 AU AU2002320198A patent/AU2002320198B2/en not_active Expired
- 2002-06-28 CN CN201310654136.XA patent/CN103755787B/zh not_active Expired - Fee Related
- 2002-06-28 JP JP2003510760A patent/JP4593106B2/ja not_active Expired - Fee Related
- 2002-06-28 MX MXPA04000151A patent/MXPA04000151A/es active IP Right Grant
- 2002-06-28 IL IL15967102A patent/IL159671A0/xx unknown
- 2002-06-28 CA CA2490538A patent/CA2490538C/en not_active Expired - Lifetime
- 2002-06-28 NZ NZ530723A patent/NZ530723A/en not_active IP Right Cessation
- 2002-06-28 EP EP02749703A patent/EP1404877B1/en not_active Expired - Lifetime
- 2002-06-28 CN CN201110025233.3A patent/CN102174079B/zh not_active Expired - Fee Related
- 2002-06-28 CN CN201210307132.XA patent/CN102875646B/zh not_active Expired - Fee Related
- 2002-06-28 AT AT02749703T patent/ATE454399T1/de not_active IP Right Cessation
- 2002-06-28 WO PCT/US2002/020599 patent/WO2003004601A2/en not_active Ceased
-
2003
- 2003-12-31 IL IL159671A patent/IL159671A/en unknown
-
2007
- 2007-09-14 US US11/855,495 patent/US7670850B2/en not_active Expired - Fee Related
- 2007-09-14 US US11/855,519 patent/US7678582B2/en not_active Expired - Fee Related
- 2007-09-14 US US11/855,586 patent/US7670852B2/en not_active Expired - Fee Related
- 2007-09-14 US US11/855,539 patent/US7670851B2/en not_active Expired - Fee Related
- 2007-09-14 US US11/855,616 patent/US7695977B2/en not_active Expired - Fee Related
-
2008
- 2008-10-12 IL IL194710A patent/IL194710A/en active IP Right Grant
-
2010
- 2010-01-26 US US12/693,854 patent/US8012700B2/en not_active Expired - Fee Related
- 2010-11-21 IL IL209472A patent/IL209472A/en not_active IP Right Cessation
- 2010-11-21 IL IL209481A patent/IL209481A/en not_active IP Right Cessation
- 2010-11-22 IL IL209509A patent/IL209509A/en not_active IP Right Cessation
-
2011
- 2011-08-12 US US13/208,801 patent/US20120009605A1/en not_active Abandoned
Non-Patent Citations (2)
| Title |
|---|
| Roussev et al. Am J Reprod Immunol, 1995. 33(1): 68-73 Abstract * |
| Roussev et al. Mol Hum Reproduct, 1996. 2(11): 883-887 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8012700B2 (en) | Assays for preimplantation factor and preimplantation factor peptides | |
| AU2002320198A1 (en) | New assays for preimplantation factor and preimplantation factor peptides | |
| AU2004284097B2 (en) | PIF peptides biologic activities, site of action, and the antibody to detect PIF | |
| US8222211B2 (en) | Methods of administering PIF agonist peptides and uses thereof | |
| Dorjee et al. | Monoclonal antibodies as direct probes for human sperm acrosome reaction | |
| CA2894868C (en) | Pif peptides biologic activities, site of action, and the antibody to detect pif | |
| EP1680442A2 (en) | Pif peptides biologic activities, site of action, and the antibody to detect pif |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |